Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) just unveiled an announcement.
SNBL has announced an update on its U.S. subsidiary Satsuma Pharmaceuticals, which is continuing negotiations for a partnering arrangement for Atzumi™, an intranasal migraine treatment, with discussions still in progress. The company’s current full-year forecast for the fiscal year ending March 31, 2026 does not include any revenue contribution from Satsuma and only assumed Satsuma’s costs for the first half of 2025, but SNBL now expects to recognize additional second-half costs from Satsuma in its consolidated results and is reviewing its earnings forecast, promising to disclose the financial impact once there is greater visibility.
The most recent analyst rating on (JP:2395) stock is a Buy with a Yen2042.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL), listed on the Tokyo Stock Exchange Prime Market under ticker 2395, operates in the biomedical and pharmaceutical sector, with activities that include drug development and related services through consolidated subsidiaries such as U.S.-based Satsuma Pharmaceuticals, Inc.
Average Trading Volume: 260,776
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen69.61B
For detailed information about 2395 stock, go to TipRanks’ Stock Analysis page.